Helius Medical Technologies, INC Form 4 insider transactions

Choon Wee Chee, CEO and President and a Director of Helius Medical Technologies, Inc., received 923,000 shares of common stock on July 31, 2026.

Summer Wisdom Holdings Ltd reported changes in beneficial ownership of Helius Medical Technologies, Inc. common stock on May 11, 2026.

Director Cosmo Yi Jiang exercised warrants for 1,005,040 shares of Solana Co common stock and withheld 610 shares for tax obligations.

Director Cosmo Yi Jiang acquired 1,005,040 warrants for Solana Co (HSDT) via a transfer agreement with Pantera Capital.

Solana Co Director Sergio Mello was granted restricted stock units and stock options under the company's equity incentive plan.

Director Michel Kai Tai Lee of Solana Co was granted stock options and restricted stock units under the company's equity incentive plan.

Solana Co Director Edward M. Straw was granted restricted stock units and stock options under the company's equity incentive plan.

Walter Blane, a Director at Solana Co, has acquired restricted stock units and stock options as part of the company's equity incentive plan.

Edward M. Straw, a Director at Solana Co, has filed a Form 4 detailing the acquisition of restricted stock units and adjustments due to reverse stock splits.

Solana Co. Director Walter Blane has reported the grant of restricted stock units (RSUs) and subsequent vesting, adjusted for multiple reverse stock splits.

Fusion Summer Ltd reported a pro-rata distribution-in-kind of 1,453,277 shares of Solana Co Class A Common Stock.

Executive Chairman Choon Wee Chee reports the vesting of 1,109,118 RSUs and the acquisition of strategic advisory warrants.

Solana Co Director Sherrie L. Perkins acquired restricted stock units and stock options following a grant under the company's equity incentive plan.

Solana Co Director Paul Buckman acquired restricted stock units and stock options, with a portion vesting immediately and the remainder subject to continued service.

Director Walter Blane acquired restricted stock units and stock options in Solana Co on March 31, 2026, as part of the company's equity incentive plan.

Helius Medical Technologies, Inc. Chief Medical Officer Antonella R. Favit-Van Pelt was granted 17,500 stock options with an exercise price of $9.76 per share.

Helius Medical Technologies' CFO and Director, Jeffrey S. Mathiesen, was granted 26,200 stock options with an exercise price of $9.76, vesting over time.

Helius Medical Technologies, Inc. Director Walter Blane was granted 2,600 stock options with an exercise price of $9.76, vesting over time.

Helius Medical Technologies, Inc. director Edward M. Straw was granted 2,600 stock options with an exercise price of $9.76, vesting over time to align with long-term company performance.

Helius Medical Technologies, Inc. Director Paul Buckman was granted 2,600 stock options under the company's 2022 Equity Incentive Plan, with an exercise price of $9.76.

Helius Medical Technologies, Inc. (HSDT) reports that its President and CEO, Dane Andreeff, was granted 52,400 stock options with an exercise price of $9.76 under the company's 2022 Equity Incentive Plan.

Sherrie L. Perkins, a Director at Helius Medical Technologies, Inc. (HSDT), was granted 2,600 stock options with an exercise price of $9.76 per share, vesting over time.

Director Sherrie L. Perkins of Helius Medical Technologies acquired 10,732 stock options on January 6, 2025, under the company's 2022 Equity Incentive Plan.

Helius Medical Technologies' Chief Medical Officer, Antonella R. Favit-Van Pelt, was granted stock options for 95,892 shares under the company's 2022 Equity Incentive Plan.

Director Blane Walter of Helius Medical Technologies acquires stock options under the company's 2022 Equity Incentive Plan.

Jeffrey S. Mathiesen, CFO and Treasurer of Helius Medical Technologies, was granted stock options for 139,857 shares under the company's 2022 Equity Incentive Plan.

Dane Andreeff, CEO of Helius Medical Technologies, was granted a stock option to purchase 279,715 shares of Class A Common Stock on January 6, 2025.

Director Paul Buckman received stock options for Helius Medical Technologies, Inc. under the 2022 Equity Incentive Plan.

Director Edward M. Straw receives stock options in Helius Medical Technologies under the company's 2022 Equity Incentive Plan.

Antonella R. Favit-Van Pelt, Chief Medical Officer of Helius Medical Technologies, received a grant of 277,000 stock options on July 2, 2024.